Medtronic Australasia Pty Ltd.
97 Waterloo Road North Ryde, NSW 2113
Phone: 1800 777 808

CGM INITIATIVE FAQ

What is CGM?

Continuous Glucose Monitoring (CGM) technology enables you to monitor your glucose levels 24 hours a day through a sensor that connects to an insulin pump, receiver or smartphone. In essence, CGM provides a more complete picture of your glucose levels by giving you warnings of lows and highs that an HbA1C reading or blood glucose monitoring alone cannot always identify.

What is the CGM Initiative?

The Australian Government has announced that it will contribute to the cost of CGM technology for certain children and young adults under 21 years old facing extra challenges managing their diabetes.  Approved CGM products will be available on the National Diabetes Services Scheme (similar to insulin pump consumables).

Who can I speak to at Medtronic to learn more about CGM technologies?

To learn more about CGM and how it can help you better manage your diabetes, please call the Medtronic Global HelpLine on 1800 777 808.

When will subsidised CGM be available?

The Australian Government announced that as of the 1st of April 2017 it will contribute to the cost of CGM technology for eligible children and young adults under 21 years old facing extra challenges managing their diabetes.

Ref: http://www.health.gov.au/internet/main/publishing.nsf/Content/MC15-004873-continuous-glucose-monitors

Why is funding for CGM important?

The Australian Government is aware of the significant impact that diabetes has on individuals and their families, and is committed to working towards the broad prevention of the disease, and its associated complications, in the Australian community. A National Diabetes Strategy (2016-20) has been developed which will guide national action and priorities to prevent diabetes and support Australians living with diabetes.

During the 2016 Federal Election, the Government committed $54 million over four years to subsidise continuous glucose monitoring (CGM) technology to assist children and young adults under 21 years of age who face extra challenges managing their type 1 diabetes.

This group may have impaired awareness of symptoms relating to severe hypoglycaemia, and can be protected by CGM technology from the consequences of severe hypoglycaemia (i.e. seizure, coma and potential death).

What are the differences between each Medtronic CGM system? I.e. Guardian 2 Link, MiniLink, Guardian Connect

  • Guardian 2 Link:             CGM paired with the MiniMed 640G insulin pump
  • MiniLink:                         CGM paired with the MiniMed Veo Paradigm insulin pump
  • Guardian Connect:         Standalone CGM system that pairs with the user’s smartphone (Apple iPhone or iPod Touch)

What are the differences between the CGM products available in Australia?

   

Guardian 2 Link CGM

MiniLink CGM

Guardian Connect

Continuous Glucose Monitor

Yes

Yes

Yes

Pump / Phone Compatibility

MiniMed 640G Pump

Paradigm Veo Pump,  Paradigm Real-Time Pumps

Apple iOS
(iPhone, iPod Touch, iPad)

Real-time values on receiver

Yes

Yes

Yes

Share reports with healthcare professionals

If HCP links CareLink Professional to CareLink Personal, they can access up-to-date reports following patient upload

If HCP links CareLink Professional to CareLink Personal, they can access up-to-date reports following patient upload

If HCP links CareLink Professional to CareLink Personal, they can access up-to-date reports daily

Transmitter Memory Storage

10 hours

40mins

14 days

Transmitter / Sensor use/life

  • Transmitter: expected service life is at least 1 year depending on patient usage
  • Sensor: 6-day wear sensor is fully disposable
  • Transmitter: expected service life is at least 1 year depending on patient usage
  • Sensor: 6-day wear sensor is fully disposable
  • Transmitter: expected service life is at least 1 year depending on patient usage
  •  Sensor: 6-day wear sensor is fully disposable

Sensor

Enlite

Enlite

Enlite

Calibrations

2x day

2x day

2x day

Alerts

Yes

Yes

Yes

Remote Partner Notification

No

No

Yes, up to 5 registered Care Partners AND optional SMS

How do I know if I am eligible to access funded CGM? What is the eligibility criteria?

Eligibility criteria

There are two categories of eligibility and a child or young person must meet one of these to access subsidised CGM products through the NDSS. A child 10 years or younger must meet Category (A) criteria, and a child or young person aged 11 years to less than 21 years must meet Category (B) criteria*.

 

Category (A)

Children 10 years of age and younger with type 1 diabetes will be eligible for subsidised access to CGM with alarms if they fulfil all of the following criteria:

  • the child is aged up to ten (10) years of age with type 1 diabetes; and
  • the child is expected to benefit clinically from the use of CGM; and
  • the family/carer has the willingness and capability to use CGM; and
  • the family/carer has the commitment to actively participate in a diabetes management plan which incorporates CGM.

 

Those children who turn 11 and have been accessing CGM products through the initiative will continue to have subsidised access. They will not need to be reassessed under Category B.

 

Category (B)

Children and young people with type 1 diabetes aged from 11 years to less than 21 years will be eligible for subsidised access to CGM with alarms if they fulfil all of the following criteria:

  • the individual is expected to benefit clinically from the use of CGM: and
  • the individual or family/carer has the willingness and capability to use CGM; and
  • the individual or family/carer has the commitment to actively participate in a diabetes management plan which incorporates CGM.

 

and they fulfil one or more of the following criteria:

  • frequent significant hypoglycaemia - more than one episode a year of significant hypoglycaemia requiring external, third party assistance; and/or
  • impaired awareness of hypoglycaemia; and/or
  • inability to recognise, or communicate about, symptoms of hypoglycaemia; and/or
  • significant fear of hypoglycaemia for the child/young person or a family member/carer which is seriously affecting the health and wellbeing of those persons or contributing to hyperglycaemia as a reaction to this fear.

 

For young people in either category, subsidised access to CGM products will cease once they reach 21 years of age.

The authorised health professionals for CGM assessment are Endocrinologists, Credentialed Diabetes Educators, and Physicians, Paediatricians or Nurse Practitioners specialising in diabetes. They will have the authority to submit an application to the NDSS for approval.

What products are available to me if I am eligible?

There are a number of different CGM solutions you can choose from:

  • If you are already using a Medtronic Pump or are Interested on starting on Medtronic Insulin Pump Therapy:
    • Guardian 2 Link CGM (paired with the MiniMed 640G insulin pump)
    • MiniLink CGM (paired with Paradigm Veo or Paradigm Real-Time insulin pump)
  • If you are  not using an insulin pump
    • Guardian Connect CGM (Standalone system)

How do I access subsidised CGM technology?

Please consult your healthcare professional who will have the authority to submit eligible patients to the National Diabetes Services Scheme for approval.

The Continuous Glucose Monitoring Eligibility Assessment form will be available from 1 April 2017 at www.ndss.com.au/CGM

Who can prescribe subsidised CGM technology?

The authorised health professionals for CGM assessment are Endocrinologists, Credentialed Diabetes Educators, and Physicians, Paediatricians or Nurse Practitioners specialising in diabetes. They will have the authority to submit an application to the NDSS for approval.

What if I have an existing sensor subscription and am eligible to access funded CGM?

Please consult your healthcare professional who will have the authority to submit eligible patients to the National Diabetes Services Scheme for approval.                                                                                           

Upon approval of funded CGM by the National Diabetes Services Scheme, your existing subscription will need to be cancelled by Medtronic Customer Service.  For more information on how to cancel your subscription, please contact the Global HelpLine on 1800 777 808.

How do I collect a Medtronic CGM product once I have been approved by my healthcare professional and the NDSS?

Once you have received confirmation of your eligibility to access funded CGM, your details will be updated on the National Diabetes Services Scheme system:

  1. If you are using CGM for the first time - your healthcare professional will submit your CGM order for fulfillment and a follow-up consultation will need to be arranged with your healthcare professional for the CGM start.  At the CGM Start you will receive your CGM Starter Kit
  2. If you are already using CGM – you can obtain ongoing access to sensors via your local NDSS Pharmacy Access Point

Medtronic Insulin Pump User - Minimed Veo or MiniMed 640G - On a sensor subscription. I have an existing MiniMed Insulin Pump sensor subscription and am eligible to access funded CGM? How do I cancel my sensor subscription?

When you receive approval of funded CGM by the National Diabetes Services Scheme, your existing sensor subscription will need to be cancelled by our Medtronic Customer Service team. Please contact the Global HelpLine on 1800 777 808.

Medtronic Insulin Pump User - Guardian Connect - On a sensor subscription. I have an existing Guardian Connect sensor subscription and am eligible to access funded CGM? How do I cancel my sensor subscription?

When you receive approval of funded CGM by the National Diabetes Services Scheme, your existing sensor subscription will need to be cancelled by our Medtronic Customer Service team. Please contact the Global HelpLine on 1800 777 808.

Medtronic iPort User

I have purchased iPort am I eligible to access funded CGM?

Please consult your healthcare professional who will have the authority to submit eligible patients to the National Diabetes Services Scheme for approval.